1. Orasure Technologies is a Pennsylvania-based developer of diagnostic tests for HIV and hepatitis C antibodies, solutions for testing abusive drugs and cryosurgical products. As The Motley Fool notes, the company has yet to meet a profit but they are improving financially and recently formed a partnership with AbbVie. They are also developing a test for Ebola.
2. Orexigen Therapeutics is a La Jolla, Calif.,-based developer of prescription drugs to treat obesity and it won regulatory approval for a weight-loss drug, Contrave, last September. Orexigen is losing money but recently secured European regulatory approval and data from its Light Study claimed Contrave can improve cardiovascular outcomes. “The average one-year price target for Orexigen reflects an increase of nearly 70 percent above the current price of the stock,” reports The Motley Fool.
3. Pacific Biosciences of California is a Menlo Park, Calif.,-based genetic sequencing leader who have yet to see profits, but according to The Motley Fool,they are currently seeing revenue growth — from less than $2 million in 2010 to over $60 million last year. They also have the possibility of being bought by Roche.
More articles on ASC issues:
136 ASC women leaders to know
U.S. health spending sees acceleration: 5 key findings
4 key statistics on how physicians are being paid
